AbbVie – Patient Worthy

FDA Approves Revolutionary Oral Combination Therapy for Chronic Lymphocytic Leukemia, Offering Patients Freedom from Long-Term Treatment

Post author:Bree Clare
Post published:March 5, 2026
Post category:Chronic Lymphocytic Leukemia

AbbVie has announced a landmark regulatory milestone with the US FDA's approval of a supplemental new drug application (sNDA) for the combination of Venclexta (venetoclax) and acalabrutinib as a first-line…

Parkinson’s: Newly Approved Drug Gives Advanced-Stage Patients Longer Periods of Relief

Post author:Rose Duesterwald
Post published:January 17, 2025
Post category:Parkinson's Disease

The FDA’s recent approval of AbbVie’s new combination therapy provides patients with longer-lasting control of movements. As described recently in Biopharmadive, Parkinson’s disease is characterized by uncontrolled muscle movements or…

FDA Approves Revolutionary Oral Combination Therapy for Chronic Lymphocytic Leukemia, Offering Patients Freedom from Long-Term Treatment

Parkinson’s: Newly Approved Drug Gives Advanced-Stage Patients Longer Periods of Relief

Let’s Work Together!

Keep Up to Date

Learn More